You are here

A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within the United Kingdom

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Aberdeen, Grampian, AB25 2ZD United Kingdom
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Ocular Hypertension, Open Angle Glaucoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
40 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Unilateral or bilateral primary open angle glaucoma, capsular glaucoma, pigmentary
glaucoma or ocular hypertension.

- Open angle glaucoma appearing more than 6 months after cataract surgery is recognized
as primary open angle glaucoma. (individuals requiring treatment bilaterally must
fulfill eligibility criteria for both eyes.)

- IOP of 22mmHg or higher obtained during the pre-study period.

- Patients currently not treated or on single-drug treatment for the elevated IOP are
eligible after a medication free period (wash-out) of:

1. 3 weeks for B-adrenergic antagonists

2. 2 weeks for adrenergic agonists

3. 5 days for cholinergics and oral carbonic anhydrase inhibitors.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- History of acute angle closure.

- Severe trauma at any time.

- Intraocular surgery or argon laser trabeculoplasty within 6 months.

- Current use of contact lenses.

- History of severe dry eye syndrome.

- Ocular inflammation/infection with three months of inclusion.

- Any condition preventing reliable applanation tonometry.

- Unacceptable finding at pre-study ocular examination as specified in the Case Report
Forms.

- In Investigator regards monotherapy insufficient with respect to optic nerve head
and/or visual field status.

- Treatment of elevated IOP with any topical B-adrenergic antagonist regularly for a
period longer than 3 months and/or treatment at any time during 6 months prior to
study start.

- Cardiac failure, sinus bradycardia, second and third degree of atrio-ventricular
block.

- Bronchial asthma, history of bronchial asthma or chronic obstructive pulmonary
disease.

- Having participated in any other clinical study within the last month.

NCT00751049
Pfizer
Completed
A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within the United Kingdom

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Glaucoma, Ocular Hypertension
NCT00143208
All Genders
18+
Years
Multiple Sites
Open Angle Glaucoma, Ocular Hypertension
NCT00140049
All Genders
18+
Years
Multiple Sites
Open-Angle Glaucoma, Ocular Hypertension
NCT00143429
All Genders

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now